Andrew J. Armstrong, MD

Articles

Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC

May 31st 2023

Andrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

May 8th 2023

Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.

Closing Thoughts on the Future of mCRPC Treatment

May 8th 2023

Matthew Manning, MD, and Andrew Armstrong, MD, discuss the remaining unmet needs in mCRPC, clinical trials and novel agents to look out for, and share practical advice for other clinicians treating patients with the disease.

Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

May 1st 2023

Centering discussion on a patient profile of mCRPC with asymptomatic bone metastases, experts share best approaches to treating and optimizing outcomes for such patients, including supplement recommendations to prevent bone fractures.

Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

May 1st 2023

Drs Armstrong and Manning review the safety and efficacy data from the ALSYMPCA trial of radium-223 in patients with mCRPC.

Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

May 1st 2023

A medical oncologist and radiation oncologist share clinical insight on how they might approach subsequent treatment selection in patients with mCRPC who have disease progression on or after radium-223.

Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases

May 1st 2023

Radiation oncologist Matthew Manning, MD, shares the patient profile of a 72-year-old man with mCRPC receiving palliative treatment with radium-223.

Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy

April 26th 2023

Drs Manning and Armstrong discuss the best treatment approaches for a patient with mCRPC and disease progression in the bone after initial radiotherapy for metastatic disease.

Patient Profile: A 78-Year-Old Man with mCRPC

April 26th 2023

Dr Andrew Armstrong presents a profile of a 78-year-old man with mCRPC with a single PSMA-avid bone metastasis and asks Dr Manning how he would treat the patient in question.

Approved Treatment Options for Patients with mCRPC

April 17th 2023

Medical oncologist Andrew Armstrong, MD, details the available treatment options for patients with mCRPC, and how recommendations vary by prior therapy and mutation status.

The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

April 17th 2023

Andrew Armstrong, MD, and Matthew Manning, MD, explain how the treatment options and typical patient outcomes in mCRPC have changed over history.

Practical Considerations in Selecting Therapy for Metastatic CRPC

August 23rd 2022

Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.

What is the Role of 177Lu-PSMA-617 in Metastatic CRPC?

August 23rd 2022

Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

Metastatic CRPC: Practical Selection and Use of PARP Inhibitors

August 16th 2022

Expert perspectives on how PARP inhibition will fit into the real-world management of patients with metastatic castration-resistant prostate cancer.

An Overview of PARP Inhibition in Metastatic CRPC

August 16th 2022

Focusing on the advent of PARP inhibitors in metastatic castration-resistant prostate cancer, genitourinary cancer specialists provide an overview of clinical trials and agents in this setting.

PTEN Loss in mCRPC: Caution Surrounding mTOR, PI3K, and AKT Inhibition

August 9th 2022

Panelists share caution toward use of mTOR-, PI3K-, and AKT-targeted therapies in the setting of PTEN loss in metastatic CRPC.

Therapy Overview: Sequencing Agents in Patients With Metastatic CRPC

August 9th 2022

A comprehensive review of available agents in the setting of metastatic CRPC, with discussion of optimal sequencing in later lines of therapy.

Metastatic Castration-Resistant Prostate Cancer: Optimal Imaging Strategies

August 2nd 2022

Expert oncologists define appropriate imaging strategies, conventional and novel, in patients with metastatic castration-resistant prostate cancer.

Clinical Scenario 3: A 76-Year-Old With Metastatic CRPC

August 2nd 2022

Shared insight on a clinical scenario of metastatic castration-resistant prostate cancer managed with androgen-deprivation therapy and docetaxel.

Addressing Unmet Needs in Nonmetastatic CRPC

July 26th 2022

Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.